NovaBay Pharmaceuticals, Inc. is an Emeryville, California based clinical-stage biopharmaceutical company, focused on products for eye care. Major products include Avenova, cleared by FDA for lid and lash cleansing as part of a regimen for Blepharitis.[1] and NeutroPhase, used in treatment of Necrotizing Fasciitis[2][3]
History
NovaBay Pharmaceuticals, Inc. was founded in 2000 by Ron Najafi to create a stable version of HOCl.[4][citation needed] Najafi, chemistry Nobel laureate Herbert C. Brown, and Purdue University Professor Dale Margerum recruited Dr. Lu Wang to become NovaBay's Director of Product Development.[citation needed] She developed the stable version of pure hypochlorous acid, without bleach impurities, which became NovaBay's first product, NeutroPhase.[5][6][7][8]
NovaBay later launched additional products named CelleRx™ for Plastic Surgery and i-Lid™ Cleanser (Now Avenova) that was cleared by FDA for lid and lash cleansing as part of a regimen for Blepharitis.[9]
References
- ↑ "NovaBay Avenova has a low toxicity but kills eyelid bacteria in dry eye or blepharitis patients".
- ↑ "Treatment of Acute Necrotizing Fasciitis Using Negative Pressure Wound Therapy and Adjunctive NeutroPhase Irrigation Under the Foam". Wounds Research. Retrieved 2019-12-11.
- ↑ "NNFF Names NovaBay's (NBY) NeutroPhase Its Official 'Flesh-Eating Disease' Wound Cleanser". StreetInsider.com. Retrieved 2019-12-11.
- ↑ "Hypochlorous Acid as a Potential Wound Care Agent Part I" (PDF).
- ↑ "510(k) Summary NeutroPhase® Skin and Wound Cleaner OTC" (PDF). Archived from the original (PDF) on October 4, 2013.
- ↑ "Hypochlorous Acid as a Potential Wound Care Agent Part II" (PDF).
- ↑ "NeutroPhase® in chronic non-healing wounds" (PDF).
- ↑ "Treatment of Acute Necrotizing Fasciitis Using Negative Pressure Wound Therapy and Adjunctive NeutroPhase Irrigation Under the Foam". [failed verification]
- ↑ "NovaBay Avenova has a low toxicity but kills eyelid bacteria in dry eye or blepharitis patients".
